Abstract
Hsp90 is a potential target for the treatment of cancer. Curcumin is a natural product used to prevent and treat cancer. 4-(4-Hydroxy-3-methoxybenzyl) curcumin (C086), a 4-arylmethyl curcumin analogue, showed lead-like properties. Western blot analyses and molecular docking study supported C086 as an Hsp90 inhibitor. Subsequently, C086 analogues were designed, synthesized and evaluated. These compounds showed increased antiproliferative activity against SKBr3 and MCF-7 breast cancer cells. The most promising compounds 7 and 10 (IC50=1.66µM and 0.509µM) were 5- fold and 17-fold better than C086 (IC50=8.55µM) against SkBr3 cell, respectively. Her2 degradation and Hsp70 induction were observed upon administration of selected 4-arylmethyl curcumin analgues, suggesting that these compounds exerted their activity through Hsp90 inhibition.
Keywords: 4-Arylmethyl curcumin analogue, Breast cancer, Curcumin, Hsp90, Hsp90 inhibitors, Molecular docking.
Letters in Drug Design & Discovery
Title:Synthesis and Evaluation of 4-arylmethyl Curcumin Analgues as Potent Hsp90 Inhibitors
Volume: 11 Issue: 8
Author(s): Yang Liu, Min Ye, Qundan Wu, Lixian Wu and Jianhua Xu
Affiliation:
Keywords: 4-Arylmethyl curcumin analogue, Breast cancer, Curcumin, Hsp90, Hsp90 inhibitors, Molecular docking.
Abstract: Hsp90 is a potential target for the treatment of cancer. Curcumin is a natural product used to prevent and treat cancer. 4-(4-Hydroxy-3-methoxybenzyl) curcumin (C086), a 4-arylmethyl curcumin analogue, showed lead-like properties. Western blot analyses and molecular docking study supported C086 as an Hsp90 inhibitor. Subsequently, C086 analogues were designed, synthesized and evaluated. These compounds showed increased antiproliferative activity against SKBr3 and MCF-7 breast cancer cells. The most promising compounds 7 and 10 (IC50=1.66µM and 0.509µM) were 5- fold and 17-fold better than C086 (IC50=8.55µM) against SkBr3 cell, respectively. Her2 degradation and Hsp70 induction were observed upon administration of selected 4-arylmethyl curcumin analgues, suggesting that these compounds exerted their activity through Hsp90 inhibition.
Export Options
About this article
Cite this article as:
Liu Yang, Ye Min, Wu Qundan, Wu Lixian and Xu Jianhua, Synthesis and Evaluation of 4-arylmethyl Curcumin Analgues as Potent Hsp90 Inhibitors, Letters in Drug Design & Discovery 2014; 11 (8) . https://dx.doi.org/10.2174/1570180811666140512221037
DOI https://dx.doi.org/10.2174/1570180811666140512221037 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phenylbutyric Acid: Simple Structure - Multiple Effects
Current Pharmaceutical Design Some Personal Memories of Bob Chanock
Infectious Disorders - Drug Targets MUC1 Story: Great Expectations, Disappointments and the Renaissance
Current Medicinal Chemistry Targeting the Ataxia Telangiectasia Mutated Protein in Cancer Therapy
Current Drug Targets Cervical Cancer: Are There Potential New Targets? An Update on Preclinical and Clinical Results
Current Drug Targets Preparation and Surface Modification of Polymeric Nanoparticles for Drug Delivery: State of the Art
Recent Patents on Drug Delivery & Formulation Adjuvant Treatment of Early Breast Cancer in the Elderly
Medicinal Chemistry The Caveolin-1 Connection to Cell Death and Survival
Current Molecular Medicine Control of Copper Status for Cancer Therapy
Current Cancer Drug Targets Editorial (Hot Topic: Translational Implications of Natural Agents)
Current Drug Targets Releasing of Herpes Simplex Virus Carrying NGF in Subarachnoid Space Promotes the Functional Repair in Spinal Cord Injured Rats
Current Gene Therapy Novel Agents Targeting Crucial Signalling Pathways in Head and Neck Squamous Cell Carcinoma, HNSCC - Preclinical Development and Data from Clinical Trials
Current Proteomics Medicinal Compound Celastrol As a Potential Clinical Anticancer Drug: Lessons Learned From Preclinical Studies
Clinical Cancer Drugs Post-Translational Modifications of PTEN and their Potential Therapeutic Implications
Current Cancer Drug Targets Recent Advances in the Development of Selective CB2 Agonists as Promising Anti-Inflammatory Agents
Current Medicinal Chemistry Recent Advancements in Nanodiamond Mediated Brain Targeted Drug Delivery and Bioimaging of Brain Ailments: A Holistic Review
Pharmaceutical Nanotechnology Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents
Current Medicinal Chemistry Effects of Olive Oil on TNF-α and IL-6 in Humans: Implication in Obesity and Frailty
Endocrine, Metabolic & Immune Disorders - Drug Targets Paclitaxel Nanoparticles Induce Apoptosis and Regulate TXR1, CYP3A4 and CYP2C8 in Breast Cancer and Hepatoma Cells
Anti-Cancer Agents in Medicinal Chemistry Dual Role of Heat Shock Proteins (HSPs) in Anti-Tumor Immunity
Current Molecular Medicine